about
sameAs
Mechanisms of Zika Virus Infection and NeuropathogenesisDengue Virus Immunopathogenesis: Lessons Applicable to the Emergence of Zika VirusSystems analysis of a RIG-I agonist inducing broad spectrum inhibition of virus infectivityCellular oxidative stress response controls the antiviral and apoptotic programs in dengue virus-infected dendritic cellsHTLV-1 Tax-mediated inhibition of FOXO3a activity is critical for the persistence of terminally differentiated CD4+ T cellsPPARγ controls Dectin-1 expression required for host antifungal defense against Candida albicans.PPARγ ligands switched high fat diet-induced macrophage M2b polarization toward M2a thereby improving intestinal Candida elimination.Nrf2, a PPARγ alternative pathway to promote CD36 expression on inflammatory macrophages: implication for malaria.Coxsackievirus cloverleaf RNA containing a 5' triphosphate triggers an antiviral response via RIG-I activationGlobal analyses revealed age-related alterations in innate immune responses after stimulation of pathogen recognition receptors.Sequence-Specific Modifications Enhance the Broad-Spectrum Antiviral Response Activated by RIG-I AgonistsNrf2-driven CD36 and HO-1 gene expression in circulating monocytes correlates with favourable clinical outcome in pregnancy-associated malariaEnhanced Influenza Virus-Like Particle Vaccination with a Structurally Optimized RIG-I Agonist as AdjuvantIn vitro and in vivo properties of ellagic acid in malaria treatment.Inhibition of dengue and chikungunya virus infections by RIG-I-mediated type I interferon-independent stimulation of the innate antiviral response.SAMHD1 host restriction factor: a link with innate immune sensing of retrovirus infection.Unmasking immune sensing of retroviruses: interplay between innate sensors and host effectors.Innate immune sensing of HIV-1 infection.RIG-I-Mediated STING Upregulation Restricts Herpes Simplex Virus 1 Infection.Crosstalk between Cytoplasmic RIG-I and STING Sensing Pathways.Host and Viral Modulation of RIG-I-Mediated Antiviral Immunity.The C-type lectin receptors dectin-1, MR, and SIGNR3 contribute both positively and negatively to the macrophage response to Leishmania infantum.IL-13 induces expression of CD36 in human monocytes through PPARgamma activation.Leishmanicidal compounds and potent PPARγ activators from Renealmia thyrsoidea (Ruiz & Pav.) Poepp. & Endl.Activation of Nrf2 Signaling Augments Vesicular Stomatitis Virus Oncolysis via Autophagy-Driven Suppression of Antiviral Immunity.RIGulation of STING expression: at the crossroads of viral RNA and DNA sensing pathways.Evaluation of Innate Immune Gene Expression Following HDAC Inhibitor Treatment by High Throughput qPCR and PhosFlow Cytometry.Transcription factors NRF2 and HSF1 have opposing functions in autophagy.Sophoraflavenone G Restricts Dengue and Zika Virus Infection via RNA Polymerase Interference.Modifications of the chemical structure of terpenes in antiplasmodial and antifungal drug research.Imported Plasmodium knowlesi malaria in a French tourist returning from Thailand.Host restriction factor SAMHD1 limits human T cell leukemia virus type 1 infection of monocytes via STING-mediated apoptosis.Type I and type III interferon-induced immune response: it's a matter of kinetics and magnitude.Breaking the barrier: membrane fusion triggers innate antiviral immunity.Correction: Systems Analysis of a RIG-I Agonist Inducing Broad Spectrum Inhibition of Virus Infectivity.Cytokines 2017 in Kanazawa: Looking beyond the horizon of integrated cytokine research from the sea of Japan.2017 Keystone Symposia at the Fairmont Banff Springs: Exploring new concepts in innate immunity and interferon signaling at the haunted castleDouble-walled carbon nanotubes trigger IL-1β release in human monocytes through Nlrp3 inflammasome activationNrf2 negatively regulates STING indicating a link between antiviral sensing and metabolic reprogrammingNitro-fatty acids are formed in response to virus infection and are potent inhibitors of STING palmitoylation and signaling
P50
Q25019713-09B2CDC3-6EE9-4261-AE99-1DA590A50978Q27010600-261007D1-1E86-4916-95C4-0618F15A6C12Q27335125-14D21BCF-B66A-4DCD-BD3C-DEB91B7BD127Q28384477-5452EAD8-3F2B-4EBD-B742-875101D765DAQ28542777-796E7EF6-2EBB-4A22-9504-6F52C13D1AFEQ33523014-32B2D144-D16D-4772-9897-D66359E19F41Q33705044-09FDD9CA-7CEC-4003-AFBD-1839CD1C0B37Q34031187-4E508B2F-17C6-4B98-8E2F-5C4CC7D8E326Q35156028-BC31288D-9782-485C-9211-DBACE20D141EQ35527203-5F29ECD8-A17E-4B2E-A41B-97D67B8E3B62Q35861232-E347BEB6-8AB3-4B6B-98C3-173477BB79D1Q36073865-E72322B0-BFAB-416B-B547-3882E20A0D18Q36086281-49A2952A-EE9F-4E04-ADA5-589379D585F5Q37115764-56DEEBC9-3440-448B-88BA-F4A13FCA88A3Q37713902-A18EDB28-4E10-4E91-8415-6FDDEC871114Q38155684-B26727DD-DAF1-45BB-8BF1-DE2E218CD4F5Q38252856-2865DDE4-14EC-4E5A-A729-4332EB9E98F6Q38285032-327B1CAF-9B8B-4706-83CF-1FEE7F1868CDQ38752535-2D8F613B-0E3A-4674-B1E0-8C32AA357576Q39078459-5BE77EE2-D5E1-4066-854F-8AB698128DD2Q39092892-1A3C8C1C-EAC8-4CDB-BBF5-AD89F91EEFBCQ39301725-21816847-2B6A-4B09-AAC6-1280A221C959Q40141303-8BF51798-599F-4D5C-871E-B4B867996309Q40189746-34035829-3925-4AC4-A835-6D166E3C5F4CQ40192795-FC12C133-4C1C-4CBA-93D2-53C81F1FDB8CQ40338727-5B739C67-15CA-4E61-AB61-446FCA267D71Q40497384-A221412B-DA4A-411A-9BAB-909FB01E4111Q41477543-5F649C94-0641-4963-ABDC-8203EB8E4DD9Q41925559-F4CE5D6B-3B07-48EA-A150-DB8643F78D08Q41942123-7D192EB0-6B6A-46A3-96E0-0E1FEEEAED19Q42072207-D0B9B7EE-28BA-464D-B021-B253378B0205Q42261339-182288C4-33E2-4F66-B075-F3B83F5C6FA2Q43544761-881F4C75-FE31-487C-90CE-B5DB7DB55383Q45880606-6A0FF476-6F31-45A4-9AB4-91206501EC9AQ48938554-C1798A55-D0CB-49DC-9B09-C4A9DE1FAA75Q50081887-5146DE4B-5D17-42AC-B3F2-33DBCDF852D0Q56482611-4F33BBA9-701F-4AFE-9B5E-E4A3CE1A72FFQ56484121-000F5D5D-F88B-4139-AAAC-EC8C3FDA6656Q57166997-138E719F-433D-47A7-BE72-A7DCE29622BFQ59355671-B29C4FB0-524A-459E-98E7-7933EE0FBC75
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
David Olagnier
@ast
David Olagnier
@en
David Olagnier
@es
David Olagnier
@sl
type
label
David Olagnier
@ast
David Olagnier
@en
David Olagnier
@es
David Olagnier
@sl
prefLabel
David Olagnier
@ast
David Olagnier
@en
David Olagnier
@es
David Olagnier
@sl
P106
P1153
16550459000
P21
P31
P496
0000-0001-6912-0674